
RTN4 AND FBXL17 GENES ARE ASSOCIATED WITH
CORONARY HEART DISEASE IN GENOME-WIDE
ASSOCIATION ANALYSIS OF LITHUANIAN FAMILIES Domarkienė I1,*, Pranculis A1, Germanas Š1, Jakaitienė A1,
Vitkus D2, Dženkevičiūtė V3, Kučinskienė ZA2, Kučinskas V1 *Corresponding Author: Ingrida Domarkienė, Department of Human and Medical Genetics, Faculty of Medicine,
Vilnius University, Santariškių str. 2, 08661 Vilnius, Lithuania; Tel.: +370-52501788; E-mail: ingrida.domarkiene@
mf.vu.lt page: 17
|
DISCUSSION
Our aim was to identify the particular genetic
factors for Lihuanian CHD patients. In order to avoid
population stratification we planned the familial
GWAS and subsequently performed TDT analysis.
Out of 12 significant SNPs, at least two (italicized
and bold rows in Table 1) had promising OR values
in addition to power and p values. Despite relatively
wide OR intervals, caused by a modest sample size,
these SNPs may indicate the potential genes that could
be involved in CHD pathogenesis.
The SNP rs17046570 is located in an intron of
the reticulon 4 coding gene (RTN4) on chromosome
2. Retic-ulons are associated with endoplasmic reticulum,
and are involved in neuroendocrine secretion
or membrane trafficking and apoptotic processes. In
particular, reticulon 4 has been identified as a potential
inhibitor of central nervous system regeneration by
means of the inhibition of neuron outgrowth [11,12].
Common RTN4 variants that are associated with
schizophrenia in the Japanese population [13] and
also blood lipid phenotypes [14], are cited. RTN4 is a
candidate gene associated with vascular cell apoptosis
and AS modulation [12]. It is thought to participate in
vascular remodeling and is a considerable new factor
for atherogenesis process [15-17]. It was also stated
that reticulons may be factors that mediate between
the apoptosis and AS processes [12]. Thus, our results
are consistent with these findings.
Another SNP on chromosome 5, rs11743737,
is located in an intron of the F-box and leucine-rich
repeat protein 17 coding gene FBXL17. The FBXL17
protein has an F-box that is a 40 amino acid motif
typical for F-box containing proteins. F-box containing
proteins together with culin and SKP1 (S-phase
kinase-associated protein 1) make up the SCF complex
(SKP1, cullin, F-box containing complex) that
is a protein ubiquitine ligase [18]. The SCF is a key
complex in the ubiquitine-proteosome system (UPS)
that is involved in 70.0-90.0% of protein degradation
processes including the degradation of a number of
proteins important for the cardiovascular system. The
UPS is also important in the regulation of endothelial
cell cycle. The effect of oxidative stress on the SCF
complex may disrupt the function of UPS and in turn
the function of the endothelium that is regulated the
by UPS [19]. According to the NCBI Gene database
review of association results [from National Human
Genome Research Institute (NHGRI) Catalogue and
association results submitted to the database of Genotypes
and Phenotypes (dbGaP)] there are many SNPs
in the FBXL17 gene region associated with the various
phenotypes including cholesterol, high-density
lipoproteins, body mass index. These findings do not
compromise our findings either. Moreover, these summarized
results might show us the complexity and
universality of the FBXL17 protein function in the
pathogenesis of different diseases. It is possible that
other SNPs that are in linkage disequilibrium with the
identified CHD associated SNPs were not identified
during this TDT analysis but may also be involved in
the development of the disease.
Conclusions. Our results suggest that the RTN4
and FBXL17 genes may be the susceptibility loci for
the CHD in the Lithuanian male population. In addition,
the genotypes of the significantly associated
SNPs with OR >7 may prove to be informative and
specific for the genetic risk of CHD evaluation in
the Lithuanian population and could be taken under
consideration in further hypothesis validation.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|